Amanta Healthcare Limited

BSE: AMANTA544502ISIN INE084K01015

Healthcare
Pharmaceuticals

Share price

₹185.05+12.40 (+7.18%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹210.00
52W low: ₹93.10
Off 52W high: -11.88%
1M return: -8.21%
3M return: +6.87%
6M return: +38.20%
1Y return: +51.12%
20D avg volume: 11,143
50 DMA: ₹185.42
200 DMA: ₹145.17

Key ratios Standalone

Market cap: ₹718.54 Cr
Current price: ₹185.05
52W high / low: ₹210.00 / ₹93.10
Face value: ₹10.00
P/E: 39.21
P/B: 3.15
EPS (TTM): ₹4.72
Book value / share: ₹58.75
ROE: —
ROCE: 10.00%
Operating margin: 21.59%
Net margin: 5.85%
Debt / equity: 1.06
Net debt: ₹153.41 Cr
Interest cover: 2.02
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 114.0 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25
Income statement
	83.13	68.80	77.00	74.49	70.89	65.31	—
	0.76	0.64	1.66	0.68	0.07	0.96	—
	83.89	69.45	78.66	75.16	70.96	66.27	—
	77.06	64.95	71.04	68.86	66.05	61.34	—
	27.73	22.73	25.13	24.23	23.73	23.83	—
	0.97	2.84	3.55	2.42	1.56	3.08	—
	11.91	11.58	11.09	10.98	10.75	10.15	—
	5.84	6.00	4.25	5.06	5.15	6.29	—
	5.28	4.69	4.75	4.67	4.66	4.64	—
	21.12	22.04	22.09	21.86	22.12	22.14	—
	6.83	4.49	7.62	6.30	4.91	4.93	—
	0.00	0.00	0.00	0.00	-2.63	0.00	—
	6.83	4.49	7.62	6.30	2.28	4.93	—
	1.97	1.18	2.09	1.68	1.07	1.42	—
	4.86	3.31	5.53	4.63	1.21	3.51	—
	1.25	0.85	1.61	1.35	0.35	1.22	—
Key metrics
	17.95	15.18	16.62	16.03	12.09	15.86	—
	21.60%	22.10%	21.60%	21.50%	17.10%	24.30%	—
	5.80%	4.80%	7.20%	6.20%	1.70%	5.40%	—
	4.00%	—	2.80%	—	2.00%	—	—
	17.30%	5.30%	—	—	—	—	—
	301.70%	-5.70%	—	—	—	—	—

Metric	TTM	FY26	FY25
Income statement
	303.42	287.68	—
	3.74	3.37	—
	307.16	291.05	—
	281.91	267.29	—
	99.82	96.93	—
	9.78	10.61	—
	45.56	42.96	—
	21.15	20.75	—
	19.39	18.73	—
	87.11	88.21	—
	25.24	23.75	—
	0.00	-2.63	—
	25.24	21.12	—
	6.92	6.25	—
	18.33	14.88	—
	5.06	4.33	—
Key metrics
	65.78	60.60	—
	21.68%	21.10%	—
	6.04%	5.20%	—
	—	10.00%	—
	—	-31.74	—
	—	3.26	—
	—	1.06	—
	—	153.41	—
	—	114.0	—
Balance sheet
	—	557.98	—
	—	237.69	—
	—	81.01	—
	—	43.02	—
	—	82.71	—
	—	18.50	—
	—	197.25	—
	—	35.89	—
	—	141.06	—
	—	234.42	—
	—	72.45	—
	—	161.97	—
	—	220.21	—
Cash flow
	—	48.45	—
	—	-93.61	—
	—	125.95	—
	—	80.19	—

Compounded growth

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 63.81%

Quarter	30 Sep 2026	September 2026	June 2026
Promoter %	63.81%	63.81%	63.81%

Holder	Type	Holding	Previous	Change
Bhavesh Girishbhai Patel	Promoter	16.31%	16.31%	0.00%
Vishal Ashokkumar Patel	Promoter	10.06%	10.06%	0.00%
Jitendrakumar Jashbhai Patel	Promoter	9.02%	9.02%	0.00%
Milcent Appliances Private Limited	Promoter	7.98%	7.98%	0.00%
Praful Jashbhai Patel	Promoter Group	5.88%	5.88%	0.00%
Bandhan Small Cap Fund	Public	5.12%	5.12%	0.00%
Shailesh Mansukhlal Mehta	Promoter Group	4.46%	4.46%	0.00%
Niranjanbhai Ishwarbhai Patel	Promoter Group	3.88%	3.88%	0.00%
Kirit Ambalal Desai	Promoter Group	3.29%	3.29%	0.00%
Jayshreeben Rohitkumar Patel	Promoter	2.57%	2.57%	0.00%
Finavenue Capital Trust - Finavenue Growth Fund	Public	1.86%	1.86%	0.00%
Perpetuity Health To Wealth (H2w) Rising Fund	Public	1.83%	1.83%	0.00%
Aarth Aif Growth Fund	Public	1.57%	1.57%	0.00%
Pravinchandra Dhanjibhai Mehta	Promoter Group	0.26%	0.26%	0.00%
Darpana J. Patel	Promoter Group	0.06%	0.06%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Amanta Healthcare Limited S	719	185.05	39.21	10.00%	—	—	+51.12%

Filings & corporate actions

Recent announcements

submission of Audio Recording of Post Results Conference Call held on November 4, 20264 Nov 2026 · Company Update / Analyst / Investor Meet
Monitoring Agency Report for the quarter ended September 30, 20264 Nov 2026 · Company Update / Monitoring Agency Report
Announcement under Regulation 30 - Investor Presentation4 Nov 2026 · Company Update / Investor Presentation
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Press Release4 Nov 2026 · Company Update / Press Release / Media Release
Statement of deviation or variation in utilization of funds, if any, under Regulation 32 of SEBI (LODR) Regulations, 20153 Nov 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
To approve unaudited Financial Results for quarter and half year ended September 30, 20263 Nov 2026 · Result / Financial Results
To approve unaudited Financial Results for quarter and half year ended 30th September 2026.3 Nov 2026 · Board Meeting / Outcome of Board Meeting
Newspaper advertisement in respect of special window for transfer and dematerialization requests of physical shares2 Nov 2026 · Company Update / Newspaper Publication
Intimation of Schedule of the Earnings Conference Call for Q2 ended September 30, 202630 Oct 2026 · Company Update / Analyst / Investor Meet
Announcement under Regulation 30 (LODR) - Resignation of Senior Management Personnel30 Oct 2026 · Company Update / Change in Management
Amanta Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Board Meeting to consider ....26 Oct 2026 · Board Meeting / Board Meeting
Certificate under Reg 74(5) of SEBI (DP) Regulations, 20186 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pravinchandra Mehta5 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Submission of Disclosures under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 - Off-Market Transfer of Equity shares1 Oct 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kirit Desai1 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pravinchandra Mehta30 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Submission of Disclosures under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 - Off Market transfer of equity shares30 Sep 2026 · Company Update / General
Intimation under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 201524 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Scrutinizer''s Report and E-voting Results - Outcome of AGM16 Sep 2026 · AGM/EGM / AGM
Scrutinizer''s Report and E-Voting results for the 31st Annual General Meeting of the Company16 Sep 2026 · AGM/EGM / AGM
Announcement under Regulation 30 (LODR) - change in management16 Sep 2026 · Company Update / Change in Management
Proceedings of the 31st Annual General Meeting ("AGM")16 Sep 2026 · AGM/EGM / AGM
Newspaper publication3 Sep 2026 · Company Update / General
Amanta Healthcare Limited Announces Commissioning of New SteriPort Line2 Sep 2026 · Company Update / General
Intimation - Regulation 36(1)(b) of the SEBI Listing Regulations25 Aug 2026 · Company Update / General
Newspaper Advertisement for dispatch of Annual Report of the 31st Annual General Meeting and e-voting information25 Aug 2026 · Company Update / Newspaper Publication
Annual Report for Financial Year 2025-2624 Aug 2026 · Company Update / General
Notice of 31st Annual General Meeting and Annual Report for F.Y. 2025-2624 Aug 2026 · AGM/EGM / AGM
Annual Report for Financial Year 2025-2624 Aug 2026 · Others / Reg. 34 (1) Annual Report
Submission of Newspaper clippings - Advertisement addressed to the Shareholders for Annual General Meeting12 Aug 2026 · Company Update / Newspaper Publication
Earnings Call Transcript for quarter ended June 30, 20268 Aug 2026 · Company Update / Earnings Call Transcript
Monitoring Agency Report for the quarter ended June 30, 20268 Aug 2026 · Company Update / Monitoring Agency Report
Publication of Financial Results in Newspapers7 Aug 2026 · Company Update / Newspaper Publication
Submission of Audio Recording of Post Results Conference Call held on August 6, 20266 Aug 2026 · Company Update / Analyst / Investor Meet
Announcement under Reg 30- Press Release5 Aug 2026 · Company Update / Press Release / Media Release
Statement of Deviation or Variation in utilization of funds, if any5 Aug 2026 · Company Update / General
Investor Presentation5 Aug 2026 · Company Update / Investor Presentation
To approve unaudited Financial Results for the Quarter ended 30th June 20265 Aug 2026 · Result / Financial Results
To approve unaudited Financial Results for quarter ended 30th June 20265 Aug 2026 · Board Meeting / Outcome of Board Meeting
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 for change in Senior Management Personnel of the Company5 Aug 2026 · Company Update / Change in Management

Board meetings

3 Nov 2026 Board Meeting - Financial Results
5 Aug 2026 Board Meeting - Financial Results